Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals Trading Down 4.6%

NASDAQ SNDX opened at $19.69 on Monday. Syndax Pharmaceuticals has a one year low of $8.58 and a one year high of $22.73. The company has a debt-to-equity ratio of 2.78, a quick ratio of 4.42 and a current ratio of 4.64. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.45 and a beta of 0.46. The company’s 50-day simple moving average is $20.85 and its two-hundred day simple moving average is $17.78.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SNDX. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. UBS Group boosted their price target on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. decreased their price objective on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. BTIG Research reiterated a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the completion of the sale, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the transaction, the chief financial officer owned 140,429 shares in the company, valued at approximately $2,953,221.87. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 30,063 shares of company stock valued at $628,332. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Large investors have recently made changes to their positions in the stock. WINTON GROUP Ltd purchased a new stake in Syndax Pharmaceuticals in the third quarter valued at approximately $346,000. The Manufacturers Life Insurance Company raised its position in Syndax Pharmaceuticals by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,149 shares of the company’s stock worth $413,000 after buying an additional 2,479 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Syndax Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after acquiring an additional 3,094 shares during the period. Caxton Associates LLP purchased a new stake in shares of Syndax Pharmaceuticals in the 1st quarter valued at $257,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth $252,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.